Fig. 3

Lipidomic analysis of LDL from breast tumor and control patients. A) PCA of lipids in tumor (T) and control (C) samples. LDL was isolated by UC from plasma of breast cancer patients or healthy women and underwent lipidomic analysis using Waters ACQUITY I class UPLC system coupled to a mass spectrometer (Thermo Exactive Plus Orbitrap). B) Comparison of representative lipids between tumor and control samples. To identify significant differences, a two-sided t-test was used. PE- phosphatidylethanolamine, TG - triglyceride, LPC– lysophosphatidylcholine, PS - phosphatidylserine, PC– phosphatidylcholine, PI– phosphatidylinositol, * (p < 0.05), ** (p < 0.01), **** (p < 0.0001). C) Comparison of main lipid classes between tumor and control samples. For each class, average folds of all lipid species within the class were averaged and presented as relative peak area. To identify significant differences, a two-sided t-test was used. PE- phosphatidylethanolamine, Cer– ceramide, PA– phosphatidic acid, LPC– lysophosphatidylcholine, LPE– lysophosphatidylethanolamine, SM- sphingomyelin, PC– phosphatidylcholine, ChE– cholesterol ester, PI– phosphatidylinositol, NS– non significant, * (p < 0.05), ** (p < 0.01), **** (p < 0.0001)